/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
GenePHIT phase 2 study design: a double blind, placebo-controlled trial to assess efficacy, safety, and tolerability of AB-1002 gene therapy in adults with heart failure
Event: ESC Congress 2024
Topic: Trial Design
Session: Cardiovascular risk and interventions: comparisons, disparities, and clinical trials
